This trial will test if two doses of a high-dose influenza vaccine are more effective than two doses of a standard dose influenza vaccine in lung transplant recipients.
- Immunization, Infection
- Transplant Infection
2 Primary · 2 Secondary · Reporting Duration: Day 56 (post-vaccination)
Awards & Highlights
2 Treatment Groups
Two Doses Standard Dose Quadrivalent Inactivated Influenza Vaccine
1 of 2
Two Doses High Dose Quadrivalent Inactivated Influenza Vaccine
1 of 2
270 Total Participants · 2 Treatment Groups
Primary Treatment: High Dose Quadrivalent Inactivated Influenza Vaccine · No Placebo Group · Phase 2
Who is running the clinical trial?
Age Any Age · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How many participants are currently being monitored for this clinical experiment?
"Affirmative, the clinicaltrials.gov database shows that this research is actively seeking to enroll participants. The study was first advertised on November 7th 2022 and its details have been updated most recently on November 18th of the same year. 270 individuals are needed for completion at one single site." - Anonymous Online Contributor
Are there still openings for participants to join this experiment?
"Affirmative. Clinicaltrials.gov data reveals that this study, first posted on November 7th 2022 is currently recruiting patients for enrollment. Approximately 270 subjects need to be enrolled from 1 particular medical centre." - Anonymous Online Contributor
Is High Dose Quadrivalent Inactivated Influenza Vaccine a secure method of immunization for patients?
"Taking into consideration the Phase 2 status of this High Dose Quadrivalent Inactivated Influenza Vaccine, our team at Power assigned it a rating of two out of three for safety due to existing data on its precautionary properties but lack thereof regarding efficacy." - Anonymous Online Contributor